KDR and neoplasm: Preclinical and clinical studies have demonstrated that small molecule inhibitors of the VEGF pathway have anti-tumor activity in some pediatric malignancies; however, it is still unclear which pediatric indications may receive the most benefit from anti-VEGFR2 therapy, either alone or in combination with chemotherapy [14–18].